Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07572825Phase 1Not Yet Recruiting

Assessing the Safety and Tolerability of NMN in DHDDS-CDG

Role: lead

NCT05402332Phase 2Not Yet Recruiting

Evaluating the Efficacy and Safety of D-galactose in PGM1-CDG (AVTX-801)

Role: lead

NCT05402345Phase 2Active Not Recruiting

A Study of GlcNAc on Tear Production in NGLY1-CDDG

Role: lead

NCT05402384Phase 2Not Yet Recruiting

AVTX-801 D-galactose Supplementation in SLC35A2-CDG

Role: lead

All 4 trials loaded